Sichan Kelun-Biotech Biopharmaceutical’s sac-TMT (sacituzumab tirumotecan) has posted positive results in a late-stage trial in non-small cell lung cancer (NSCLC). During the Phase III OptiTROP-Lung05 ...
The combination of Merck's Keytruda and Pfizer and Astellas' Padcev recently made waves in bladder cancer—and the broader oncology world—by delivering a massive life-extension benefit against ...
Merck Touts Phase 3 Success For $20B Cancer Drug Keytruda In Untreated Head And Neck Cancer Patients
On Tuesday, Merck & Co Inc (NYSE:MRK) announced that the Phase 3 KEYNOTE-689 trial of Keytruda (pembrolizumab), as a perioperative treatment for patients newly diagnosed with stage III or IVA, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results